GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

Research output: Contribution to journalArticle

Standard

GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. / Ahrén, Bo.

In: Current Diabetes Reports, Vol. 7, No. 5, 2007, p. 340-347.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

AU - Ahrén, Bo

PY - 2007

Y1 - 2007

N2 - Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A(1c) by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia.

AB - Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A(1c) by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia.

M3 - Article

VL - 7

SP - 340

EP - 347

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1539-0829

IS - 5

ER -